A report on clinical outcomes and risks after post-ibrutinib transplant addresses how relapsed or refractory mantle cell lymphoma patients fare once they move from targeted therapy to transplant-based approaches. The content highlights an era of rapid targeted-treatment growth but emphasizes the persistence of poor outcomes in difficult-to-treat disease. The discussion centers on both outcomes and transplant-associated risk considerations after prior ibrutinib exposure. For hematology teams, the key decision points involve patient selection for transplant and managing complication risk when targeted therapy has been used before consolidation. As clinicians weigh sequencing strategies across relapsed MCL, the new analysis provides additional evidence for counseling on expected benefits and potential hazards.